ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Average Recommendation of “Moderate Buy” by Brokerages

ProQR Therapeutics N.V. (NASDAQ:PRQR) has been assigned a consensus rating of “Moderate Buy” from the eight ratings firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and six have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $7.25.

A number of research firms recently commented on PRQR. Citigroup reissued a “market outperform” rating on shares of ProQR Therapeutics in a research report on Wednesday, May 27th. Oppenheimer initiated coverage on shares of ProQR Therapeutics in a report on Thursday, March 12th. They issued an “outperform” rating and a $9.00 price target on the stock. Weiss Ratings raised ProQR Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 8th. Chardan Capital reiterated a “buy” rating and set a $4.00 price objective on shares of ProQR Therapeutics in a report on Thursday, April 9th. Finally, Wall Street Zen downgraded ProQR Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th.

Institutional Investors Weigh In On ProQR Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Osaic Holdings Inc. grew its stake in shares of ProQR Therapeutics by 59.6% during the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 4,500 shares during the last quarter. Persistent Asset Partners Ltd raised its position in shares of ProQR Therapeutics by 24.5% in the 4th quarter. Persistent Asset Partners Ltd now owns 45,154 shares of the biopharmaceutical company’s stock valued at $91,000 after purchasing an additional 8,874 shares during the last quarter. Diadema Partners LP raised its position in shares of ProQR Therapeutics by 6.2% in the 4th quarter. Diadema Partners LP now owns 167,532 shares of the biopharmaceutical company’s stock valued at $338,000 after purchasing an additional 9,838 shares during the last quarter. Bank of America Corp DE boosted its stake in ProQR Therapeutics by 6.4% in the 1st quarter. Bank of America Corp DE now owns 185,110 shares of the biopharmaceutical company’s stock worth $300,000 after purchasing an additional 11,186 shares in the last quarter. Finally, Raymond James Financial Inc. boosted its stake in ProQR Therapeutics by 15.2% in the 3rd quarter. Raymond James Financial Inc. now owns 110,270 shares of the biopharmaceutical company’s stock worth $235,000 after purchasing an additional 14,549 shares in the last quarter. Institutional investors and hedge funds own 32.65% of the company’s stock.

ProQR Therapeutics Price Performance

PRQR opened at $1.44 on Monday. The firm has a market capitalization of $151.72 million, a PE ratio of -2.88 and a beta of 0.07. The business’s 50-day moving average is $1.63 and its two-hundred day moving average is $1.74. ProQR Therapeutics has a 1 year low of $1.33 and a 1 year high of $3.10.

ProQR Therapeutics (NASDAQ:PRQR) last released its quarterly earnings results on Tuesday, May 12th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.15). ProQR Therapeutics had a negative net margin of 331.33% and a negative return on equity of 84.87%. The business had revenue of $2.35 million for the quarter, compared to analysts’ expectations of $5.19 million. As a group, sell-side analysts expect that ProQR Therapeutics will post -0.57 EPS for the current year.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.